Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 3Glioma 2Glioblastoma 2Astrocytoma 2Sarcoma 1Peritoneal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Bone Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

Carboplatin 27Paclitaxel 23Cisplatin 22Gemcitabine 17pembrolizumab 15Fluorouracil 9Pemetrexed 8Everolimus 8Docetaxel 8Cetuximab 8Radiotherapy, Intensity-Modulated 7Radiotherapy 7130-nm albumin-bound paclitaxel 7Sorafenib 6Nivolumab 6Bevacizumab 6Axitinib 6epothilone B 5Sunitinib 5Radiation 5Panitumumab 5Cyclophosphamide 5trebananib 4reolysin 4padeliporfin 4lenvatinib 4Irinotecan 4Gefitinib 4vosaroxin 3volociximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma × lentiviral minigene vaccine of COVID-19 coronavirus × Clear all
NCT01671592 2017-09-26

Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)

University of Pittsburgh

Phase 1 Completed
6 enrolled
Gastrointestinal

Carcinoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡